Mycolic acids for the control of tuberculosis

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 3, 2007, Pages 315-331

  Sekanka, Gianna ^a   Baird, Mark ^b   Minnikin, David ^c   Grooten, Johan ^d  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b BANGOR UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d GHENT UNIVERSITY   (Belgium)

Author keywords

Antibody; Biosynthesis; HIV; Macrophage; Mycobacterium; Regulatory; Serodiagnosis; T cell; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ACETAMIDE DERIVATIVE; BCG VACCINE; CERULENIN; CYCLOPROPANE DERIVATIVE; CYTOKINE; ENZYME INHIBITOR; ETHIONAMIDE; FATTY ACID SYNTHASE; GEMFIBROZIL; GENZ 10850; GENZ 8575; HYDROXY FATTY ACID; ISONIAZID; LIPID; METHYLTRANSFERASE INHIBITOR; MYCOLIC ACID; PENICILLIN G; PHOSPHONIC ACID DERIVATIVE; PROTIONAMIDE; SULFONAMIDE; THIOLACTOMYCIN; TIOCARLIDE; TRICLOSAN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG BINDING SITE; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SYNTHESIS; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LUNG ALVEOLUS MACROPHAGE; LUNG TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATHOGENICITY; PROTEIN SYNTHESIS INHIBITION; REVIEW; SERODIAGNOSIS; STRUCTURE ACTIVITY RELATION;

EID: 33847782804     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.3.315     Document Type: Review

References (113)

1. COLEBUNDERS R, LAMBERT ML: Management of co-infection with HIV and TB. BMJ (2002) 324:802-803.
2. DEVI KR, RAMALINGAM B, RAJA A: Antibody response to Mycobacterium tuberculosis 30 and 16 kDa antigens in pulmonary tuberculosis with human immunodeficiency virus co-infection. Diagn. Microbiol. Infect. Dis. (2003) 46(3):205-209.
3. WATTERSON SA, DROBNIEWSKI FA: Modern laboratory diagnosis of mycobacterial infections. J. Clin. Pathol. (2005) 53:727-732.
4. BURMAN WJ, JONES BE: Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am. J. Respir. Crit. Care Med. (2001) 164(1):7-12.
5. AARON L, SAADOUN D, CALATRONI I et al.: Tuberculosis in H1V infected patients: a compressive review. Clin. Microbiol. Infect. (2004) 10(5):388-398.
6. ORMEROD LP: Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment. Br. Med. Bull. (2005):17-24:73-74.
7. FARMER P, LÉANDRE F, MUKHERJEE JS et al.: Community-based approaches to HIV treatment in resource-poor settings. Lancet (2001) 358:404-409.
8. LEPROSY ELIMINATION PROJECT: Status rapport (2003) (draft): World Health Organization, Geneva; (2004).
9. WORLD HEALTH ORGANISATION: Buruli ulcer (2001) Fact Sheet No 199.
10. SIZAIRE V, NACKERS F, PORTAELS F: Mycobacterium ulcerans infection: control, diagnosis and treatment. Lancet Infect. Dis. (2006) 6:288-296.
11. SECHI LA, MURA M, TANDA F et al.: Identification of Mycobacterium avium subspecies paratuberculosis in biopsy specimens from patients with crohn's disease identified by in situ hybridization. J. Clin. Microbiol. (2001) 39(12):4514-4517.
12. SINGH SV, VIHAN VS: Detection of Mycobacterium avium subspecies paratuberculosis in goat milk. Small Ruminant Research (2004):article in press.
13. BRENNAN PJ, NIKAIDO H: The envelope of mycobacteria. Annu. Rev. Biochem. (1995) 64:29-63.
14. NAHID P, PAI M, HOPEWELL PC: Advances in the diagnosis and treatment of tuberculosis. Proc. Am. Thorac. Soc. (2006) 3:103-110.
15. DMITRIEV BA, EHLERS S, RIETSCHEL ET, BRENNAN PJ: Molecular mechanics of the mycobacterial cell wall: from horizontal layers to vertical scaffolds. Int. J. Med. Microbiol. (2000) 290(3):251-258.
16. MINNIKIN DE, KREMER L, DOVER LG, BESRA GS: The methyl-branched fortifications of Mycobacterium tuberculosis. Chem. Biol. (2002) 9(5):545-553.
17. BELISLE JT, VISSA VD, SIEVER TT, TAKAYAMA K, BRENNAN PJ, BESRA GS: Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science (1997) 276:1420-1422.
18. ANDERSON RJ: Structural peculiarities of acid-fast bacterial lipids. Chem. Rev. (1941) 29:225-243.
19. STODOLA FH, LESUK A, ANDERSON RJ: The chemistry of the lipids of Tubercle bacilli. LIV.. The isolation and properties of mycolic acid. J. Biol. Chem. (1938):505-513.
20. ASSELINEAU J: Sur la structure chimique des acides mycoliques isolés de Mycobacterium tuberculosis var. hominis; determination de la position de l'hydroxyle. C. R. Hebd. Seances Acad. Sci. (1950) 230:1620-1622.
21. ASSELINEAU J, LEDERER E: Structure of the mycolic acids of Mycobacteria. Nature (1950) 166(4227):782-783.
22. ASSELINEAU J: The Bacterial Lipids (1966) Hermann, Paris
23. LANEELLE G: Nature of mycolic acids from Mycobacterium paratuberculosis, application of thin layer chromatography to their fractionation. C. R. Hebd. Seances Acad. Sci. (1963) 257:781-783.
24. MINNIKIN DE: Lipids: complex lipids, their chemistry, biosynthesis and roles. In: The Biology of the Mycobacteria. (Eds). Ratledge C, Standford J. San Diego: Academic Press, Inc. (1982):95-184.
25. GASTAMBIDE-ODIER M, DELAUMENY JM, LEDERER E: Demonstration of cyclopropane rings in various mycolic acids from human and bovine strains of Mycobacterium tuberculosis. C. R. Hebd. Seances Acad. Sci. (1964) 259:3404-3407.
26. MINNIKIN DE: Nuclear magnetic resonance spectra of long-chain 1,2-disubstituted cyclopropane esters. Chem. Ind. (1966) 2167.
27. MINNIKIN DE, POLGAR N: Stereochemical studies on the mycolic acids. Chem. Comm. (1966):648-649.
28. MINNIKIN DE, POLGAR N: The methoxymycolic and ketomycolic acids from human Tubercle bacilli. Chem. Commun. (1967):916-918.
29. MINNIKIN DE, POLGAR N: The mycolic acids from human and avian Tubercle bacilli. Chem. Commun. (1967):1172-1174.
30. ETEMADI AH: Techniques microanalytiques d'etude de structure d'esters α-ramifies, β-hydroxyles. Chromatographie en phase vapeur et spectrometrie de masse. Bull. Soc. Chim. Fr. (1964):1535-1541.
31. ETEMADI AH, MIQUEL AM, LEDERER E, BARBER M: Sur la structure des acides α-mycoliques de Mycobacterium kansasii. Spectrometrie de masse a haute resolution pour des masses de 750 a 1200. Bull. Soc. Chim. Fr. (1964):3274-3276.
32. WATANABE M, AOYAGI Y, RIDELL M, MINNIKIN DE: Separation and characterization of individual mycolic acids in representative mycobacteria. Microbiology. (2001) 147(7):1825-1837.
33. WATANABE M, AOYAGI Y, MITOME H et al.: Location of functional groups in mycobacterial meromycolate chains; the recognition of new structural principles in mycolic acids. Microbiology (2002) 148(6):1881-1902.
34. DAFFE M, LANEELLE MA, ASSELINEAU C, LEVY-FREBAULT V, DAVID H: Taxonomic value of mycobacterial fatty acids: proposal for a method of analysis. Ann Microbiol (Paris). (1983) 134B(2):241-56.
35. DOBSON G, MINNIKIN DE, MINNIKIN SM et al.: Systematic analysis of complex mycobacterial lipids. In: Chemical Methods in Bacterial Systematics (Eds). Goodfellow M, Minnikin DE. Academic Press, London, (1985):237-265.
36. CHRISTENSEN H, GARTON NJ, HOROBIN RW, MINNIKIN DE, BARER MR: Lipid domains of mycobacteria studied with fluorescent molecular probes. Mol. Microbiol. (1999) 31:1561-1572.
37. VILLENEUVE M, KAWAI M, KANASHIMA H, WATANABE M, MINNIKIN DE, NAKAHARA H: Temperature dependence of the Langmuir monolayer packing of mycolic acids from Mycobacterium tuberculosis. Biochim. Biophys. Acta. (2005) 1715(2):71-80.
38. ETEMADI AH: Isomerisation de mycolates de methyle en milieu alcalin. Chem. Physics Lipids (1967) 1:165-175.
39. ASSELINEAU C, TOCANNE G, TOCANNE JF: Stereochemistry of mycolic acids. Bull. Soc. Chim. Fr. (1970) 4:1455-1459.
40. ASSELINEAU C, ASSELINEAU J: Stéréochimie de l'acide corynomycolique. Bull. Soc. Chim. Fr. (1966):1992-1999.
41. TOCANNE JF, ASSELINEAU C: Etude stéréochimique des acides aliphatiques α-ramifiés β-hydroxylés. Configuration de l'acide corynomycolique. Bull. Soc. Chim. Fr. (1968):4519-4525.
42. LACAVE C, LANEELLE M-A, DAFFE M, MONTROZIER H, ROLS M-P, ASSELINEAU C: Structural and metabolic studies of the mycolic acids of Mycobacterium fortuitum. Eur. J. Biochem. (1987) 163:369-378.
43. QUEMARD A, LANEELLE MA, MARRAK-CHI H, PROME D, DAFFE M: Structure of a hydroxymycolic acid potentially involved in the synthesis of oxygenated mycolic acids of the Mycobacterium tuberculosis complex. Eur. J. Biochem. (1997) 250:758-763.
44. DUBNAU E, LANEELLE MA, SOARES S et al.: Mycobacterium bovis BCG genes involved in the biosynthesis of cyclopropyl keto- and hydroxymycolic acids. Mol. Microbiol. (1997) 23:313-322.
45. AL DULAYYMI JR, BAIRD MS, ROBERTS E: The synthesis of a single enantiomer of a major α-mycolic acid of Mycobacterium tuberculosis. Chem. Comm. (2003):228-229.
46. AL DULAYYMI JR, BAIRD MS, ROBERTS E: The synthesis of a single enantiomer of a major α-mycolic acid of M. tuberculosis. Tetrahedron (2005) 61:11939-11951.
47. AL DULAYYMI JR, BAIRD MS, ROBERTS E, DEYSEL M, VERSCHOOR J: The first synthesis of single enantiomers of the major methoxymycolic acid of Mycobacterium tuberculosis. Tetrahedron (2006) submitted for publication.
48. KOZA G, BAIRD MS: The first synthesis of a single enantiomer of a ketomycolic acid. (2006) submitted for publication.
49. AL DULAYYMI JR, BAIRD MS, ROBERTS E, MINNIKIN DE: The synthesis of single enantiomers of meromycolic acids from mycobacterial wax esters. Tetrahedron (2006) 62(51):11867-11880.
50. AL-DULAYYMI JR, BAIRD MS, MOHAMMED H, ROBERTS E, CLEGG W: The synthesis of one enantiomer of the α-methyl-transcyclopropane unit of mycolic acids. Tetrahedron (2006) 62:4851-4862.
51. TOSCHI G, BAIRD MS: An improved procedure for the preparation of the β-hydroxy-α-alkyl fatty acid fragment of mycolic acids. Tetrahedron (2006) 62:3221-3227.
52. BASSO LA, SANTOS DS: Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis - an update. Med. Chem. Rev. (2005) 2:393-413.
53. COLE BT, BROSCH R, PAKHILL J et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature (1998) 393:537-544.
54. TAKAYAMA K, WANG C, BESRA GS: Pathway to synthesis and processing of mycolic acids in M. tuberculosis. Clin. Microbiol. Rev. (2005) 18(1):81-101.
55. GLICKMAN MS: The mmaA2 gene of M. tuberculosis encodes the distal cyclopropane synthase of α-mycolic acid. J. Biol. Chem. (2003) 278(10):7844-7849.
56. GLICKMAN MS, CAHILL SM, WILLIAM R, JACOBS J: The M. tuberculosis cmaA2 gene encodes a mycolic acid trans-cyclopropane synthetase. J. Biol. Chem. (2001) 276(3):2228-2233.
57. BUIST PH, MACLEAN DB: The biosynthesis of cyclopropane fatty acids. I. Feeding studies with oleic acid-9,10-d2 oleic acid-8,8,11,11-d4, and L-methionine-methyl d3. Can. J. Chem. (1981) 59:828-838.
58. BUIST PH, MACLEAN DB: The biosynthesis of cyclopropane fatty acids. II. Mechanistic studies using methionine labelled with one, two, or three deuterium atoms in the methyl group. Can. J. Chem. (1982) 60:371-378.
59. PORTEVIN D, SOUSA-D'AURIA CD, HOUSSIN C et al.: A polyketide synthase catalyzes the last condensation step of mycolic acid biosynthesis in mycobacteria and related organism. PNAS (2004) 101(1):314-319.
60. HEATH RJ, WHITE SW, ROCK CO: Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. (2001) 40(6):467-497.
61. ZHANG Y: The magic bullets and tuberculosis drug targets. Annu. Rev. Pharmacol. Toxicol. (2005) 45:529-564.
62. HEATH RJ, WHITE SW, ROCK CO: Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. (2001) 40(6):467-497.
63. BAULARD AR, BETTS JC, ENGOHANG-NDONG J et al.: Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. (2000) 275(36):28326-28331.
64. SANDBORGH-ENGLUND G, ADOLFSSON-ERICI M, ODHAM G, EKSTRAND J: Pharmacokinetics of triclosan following oral ingestion in humans. J. Toxicol. Environ. Health A (2006) 69(20): 1861-1873.
65. KUO MR, MORBIDONI HR, ALLAND D et al.: Targeting tuberculosis and malaria through inhibition of enoyl reductase. J. Biol. Chem. (2003) 278(23):20751-20859.
66. FUNABASHI H, KAWAGUCHI A, TOMODA H et al.: Binding site of cerulenin in fatty acid synthetase. J. Biochem. (Tokyo) (1989) 105(5):751-755.
67. DOUGLAS JD, SENIOR SJ, MOREHOUSE C et al.: Analogues of thiolactomycin: potential drugs with enhanced anti-mycobacterial activity. Microbiology (2002) 148:3101-3109.
68. KAMALA A, SHAIKA AA, RAKESH S, YADAV JS, ARORA SK: Antitubercular agents. Part 2: new thiolactomycin analogues active against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. (2005) 15(7):1927-1929.
69. BHOWRUTH V, BROWN AK, REYNOLDS RC et al.: Symmetrical and unsymmetrical analogues of isoxyl; active agents against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. (2006) 16(18):4743-4747.
70. PHETSUKSIRI B, JACKSON M, SCHERMAN H et al.: Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J. Biol. Chem. (2003) 278(52):53123-53130.
71. COXON GD, AL DULAYYMI JR, MOREHOUSE C et al.: Synthesis and properties of methyl 5- (1'R,2'S)-(2-octadecylcycloprop-1-yl)pentanoate and other ω-19 chiral cyclopropane fatty acids and esters related to mycobacterial mycolic acids. Chem. Physics Lipids (2004) 127:35-46.
72. GLICKMAN MS, COX JS, JACOBS WR Jr: A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Moll. Cell (2000) 5:717-727.
73. RAO V, FUJIWARA N, PORCELLI SA, GLICKMAN MS: Mycobacterium tuberculosis controls host innate immune activation through cyclopropane modification of a glycolipid effector molecule. J. Exp. Med. (2005) 201(4):535-543.
74. RAO V, GAO F, CHEN B, JACOBS WR, GLICKMAN MS: Trans-cyclopropanation of mycolic acids on trehalose dimycolate suppresses Mycobacterium tuberculosis-induced inflammation and virulence. J. Clin. Investig. (2006) 116(6):1664-1667.
75. SMITH CV, SHARMA V, SACCHETTINI JC: TB drug discovery: addressing issues of persistence and resistance. Tuberculosis (2004) 84:45-55.
76. GUÉRARD C, MAUD B, COURTOIS F, DRUJON T, PLOUX O: Synthesis and evaluation of analogues of S-adenosyl-L-methionine, as inhibitors of the E. coli cyclopropane fatty acid synthase. Bioorg. Med. Chem. Lett. (2004) 14:1661-1664.
77. GUIANVARC'H D, DRUJON T, LEANG TE, COURTOIS F, PLOUX O: Identification of new inhibitors of E. coli cyclopropane fatty acid synthase using a colorimetric assay. Biochimica. Biophysica. Acta-Proteins and Proteomics (2006) 1764(8):1381-1388.
78. DUBNAU E, CHAN J, RAYNAUD C et al.: Oxygenated mycolic acids ore necessary for virulence of Mycobacterium tuberculosis in mice. Mol. Microbiol. (2000) 36(3):630-637.
79. YUAN Y, ZHU Y, CRANE DD, BARRY C III: The effect of oxygenated mycolic acid composition on the cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol. Microbiol. (1998) 29(6):1449-1458.
80. YUAN Y, BARRY CE III: A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acid in Mycobacterium tuberculosis. PNAS (1996) 93:12828-12833.
81. STOVER CK, WARRENER P, VANDEVANTER DR et al.: A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature (2000) 405:962-966.
82. AHMAD K: New tuberculosis drug enters human trials Lancet Infect. Dis. (2005) 5(8):475.
83. RONNING DR, KLABUNDE T, BESRA GS et al.: Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines. Nat. Struct. Biol. (2000) 7(2):141-146.
84. RONNING DR, VISSA V, BESRA GS, BELISLE JT, SACCHETTINI JC: Mycobacterium tuberculosis antigen 85A and 85C structures confirm binding orientation and conserved substrate specificity. J. Biol. Chem. (2004) 279(35):36771-36777.
85. GOBEC S, PLANTAN I, MRAVLJAK J et al.: Phosphonate inhibitors of antigen 85C, a crucial enzyme involved in the biosynthesis of the Mycobacterium tuberculosis cell wall. Bioorg. Med. Chem. Lett. (2004) 14(13):3559-3562.
86. KOVAC A, WILSON RA, BESRA GS et al.: New lipophilic phthalimido- and 3-phenoxybenzyl sulfonates: inibition of antigen 85C mycolyltransferase activity and citotoxicity. J. Enzyme Inhib. Med. Chem. (2006) 21(4):391-397.
87. SHARMA SK, MOHAN A: Extrapulmonary tuberculosis. Indian J. Med. Res. (2004) 120:316-356.
88. WHO GTP: WHO tuberculosis diagnostic workshop: product development guidelines. Cleaveland, Ohio. (1997):1-20.
89. KABRA SK, LODHA R, SETH V: Some current concepts on childhood tuberculosis. Indian J. Med. Res. (2004) 120:387-397.
90. BOGGIAN K, FIERZ W, VERNAZZA PL: Infrequent detection of lipoarabinomannan antibodies in human immunodeficiency virus-associated mycobacterial disease. Swiss HIV Cohort Study. J. Clin. Microbiol. (1996) 34(7):1854-1855.
91. OKUDA Y, MAEKURA R, HIROTANI A et al.: Rapid serodiagnosis of active pulmonary Mycobacterium tuberculosis by analysis of results from multiple antigen-specific tests. J. Clin. Microbiol. (2004) 42(3):1136-1141.
92. PERKINS MD, CONDE MB, MARTINS M, KRITSKI AL: Serologic diagnosis of tuberculosis using a simple commercial multiantigen assay. Chest (2003) 123(1):107-112.
93. HOUGHTON RL, LODES MJ, DILLON DC et al.: Use of multiepitope polyproteins in serodiagnosis of active tuberculosis. Clin. Diagn. Lab. Immunol. (2002) 9(4):883-891.
94. PAN J, FUJIWARA N, OKA S et al.: Anti-cord factor (trehalose 6,6′-dimycolate) IgG antibody in tuberculosis patients recognizes mycolic acids subclasses. Microbiol. Immunol. (1999) 43(9):863-869.
95. MAEKURA R, NAKAGAWA M, NAKAMURA Y et al.: Clinical evaluation of rapid serodiagnosis of pulmonary tuberculosis by ELISA with cord factor (trehalose-6,6′-dimycolate) as antigen purified from Mycobacterium tuberculosis. Am. Rev. Respir. Dis. (1993) 148(4):997-1001.
96. MORIMOTO T, TAKANASHI S, HASEGAWA Y et al.: Level of antibodies against mycobacterial glycolipid in the effusion for diagnosis of tuberculous pleural effusion. Res. Med. (2006) 100:1775-1780.
97. FUJITA Y, DOI T, SATO K, YANO I: Diverse humoral immune responses and changes in IgG antibody levels against mycobacterial lipid antigens in active tuberculosis. Microbiology (2005) 151:2065-2074.
98. FUJITA Y, DOI T, MAEKURA R, ITO M, YANO I: Differences in serological responses to specific glycopeptidolipid-core and common lipid antigens in patients with pulmonary disease due to Mycobacterium tuberculosis and Mycobacterium avium complex. J. Med. Microbiol. (2006) 55:189-199.
99. NABESHIMA S, MURATA M, KASHIWAGI K et al.: Serum antibody response to tuberculosis-associated glicolipid antigen after BCG vaccination in adults. J. Infect. Chemother. (2005) 11:256-258.
100. SCHLEICHER GK, FELDMAN C, VERMAAK Y, VERSCHOOR JA: Prevalence of anti-mycolic acid antibodies in patients with pulmonary tuberculosis co-infected with HIV. Clin. Chem. Lab. Med. (2002) 40(9):882-887.
101. VERSCHOOR JA, ONYEBUJO P: The menace of the AIDS-tuberculosis combo: any solutions? Bioessays (1999) 21(5):365-356.
102. SANSONETTI PJ: War and peace at mucosal surfaces. Nat. Rev. Immunol. (2004) 4(12):953-964.
103. STROHMEIER GR, FENTON MJ: Roles of lipoarabinomannan in the pathogenesis of tuberculosis. Microbes Infect. (1999) 1(9):709-717.
104. Hl responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr. Opin. Immunol. (2005) 17(4):374-380.
105. BRIKEN V, PORCELLI SA, BESRA GS, KREMER L: Mycobacterial lipoarabinomannan and related lipoglycans: from biogenesis to modulation of the immune response. Mol. Microbiol. (2004) 53(2):391-403.
106. TSENOVA L, ELLISON E, HARBACHEUSKI R et al.: Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. J. Infect. Dis. (2005) 192(1):98-106.
107. GEISEL RE, SAKAMOTO K, RUSSELL DG, RHOADES ER: In vivo activity of released cell wall lipids of Mycobacterium bovis bacillus Calmette-Guerin is due principally to trehalose mycolates. J. Immunol. (2005) 174(8):5007-5015.
108. IMAI K, KURITA-OCIAI T, OCIAI K: Mycobacterium bovis bacillus Calmette-Guerin infection promotes SOCS induction and inhibits IFN-γ-stimulated JAK/STAT signaling in J774 macrophages. FEMS Immunol. Med. Microbiol. (2003) 39(2):173-180.
109. AKBARI O, STOCK P, MEYER E, et al.: Role of regulatory T cells in allergy and asthma. Curr. Opin. Immunol. (2003) 15(6):627-633.
110. LISBONNE M, DIEM S, DE CASTRO KELLER A, et al.: Invariant V α 14 NKT cells are required for allergen-induced airway inflammation and hyperreactivity in an experimental asthma model. J. Immunol. (2003) 171(4):1637-1641.
111. GOODRUM MA, SIKO DG, NIEHEUS T, EICHELBAUER D, VERSCHOOR JA: Mycolic acids from Mycobacterium tuberculosis: purification by countercurrent distribution and T cell stimulation. Microbios. (2001) 106(413):55-67.
112. KORF J, STOLZ A, VERSCHOOR J, DE BAETSELIER P, GROOTEN J: The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur. J. Immunol. (2005) 35:890-900.
113. KORF JE, PYNAERT G, TOURNOY K et al.: Macrophage reprogramming by mycobacterial mycolic acid promotes a tolerogenic response in experimental asthma. Am. J. Respir. Crit. Care Med. (2006) 174:1-9.